203 related articles for article (PubMed ID: 19625947)
1. Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.
Ho SK; Perez EE; Rose SL; Coman RM; Lowe AC; Hou W; Ma C; Lawrence RM; Dunn BM; Sleasman JW; Goodenow MM
AIDS; 2009 Aug; 23(13):1631-40. PubMed ID: 19625947
[TBL] [Abstract][Full Text] [Related]
2. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
3. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.
Ho SK; Coman RM; Bunger JC; Rose SL; O'Brien P; Munoz I; Dunn BM; Sleasman JW; Goodenow MM
Virology; 2008 Sep; 378(2):272-81. PubMed ID: 18599104
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.
Larrouy L; Charpentier C; Landman R; Capitant C; Chazallon C; Yeni P; Peytavin G; Damond F; Brun-Vezinet F; Descamps D;
AIDS; 2011 Nov; 25(17):2143-8. PubMed ID: 21904187
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy.
Brumme ZL; Dong WW; Yip B; Wynhoven B; Hoffman NG; Swanstrom R; Jensen MA; Mullins JI; Hogg RS; Montaner JS; Harrigan PR
AIDS; 2004 Mar; 18(4):F1-9. PubMed ID: 15090786
[TBL] [Abstract][Full Text] [Related]
6. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
Larrouy L; Vivot A; Charpentier C; Bénard A; Visseaux B; Damond F; Matheron S; Chene G; Brun-Vezinet F; Descamps D;
AIDS; 2013 Jan; 27(1):69-80. PubMed ID: 23018441
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
Bally F; Martinez R; Peters S; Sudre P; Telenti A
AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
[TBL] [Abstract][Full Text] [Related]
8. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations.
Banke S; Lillemark MR; Gerstoft J; Obel N; Jørgensen LB
J Virol; 2009 Sep; 83(17):8916-24. PubMed ID: 19515784
[TBL] [Abstract][Full Text] [Related]
9. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.
Larrouy L; Chazallon C; Landman R; Capitant C; Peytavin G; Collin G; Charpentier C; Storto A; Pialoux G; Katlama C; Girard PM; Yeni P; Aboulker JP; Brun-Vezinet F; Descamps D;
Antimicrob Agents Chemother; 2010 Jul; 54(7):2910-9. PubMed ID: 20439606
[TBL] [Abstract][Full Text] [Related]
10.
Datir R; Kemp S; El Bouzidi K; Mlchocova P; Goldstein R; Breuer J; Towers GJ; Jolly C; Quiñones-Mateu ME; Dakum PS; Ndembi N; Gupta RK
mBio; 2020 Nov; 11(6):. PubMed ID: 33144375
[TBL] [Abstract][Full Text] [Related]
11. Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease.
Kozísek M; Henke S; Sasková KG; Jacobs GB; Schuch A; Buchholz B; Müller V; Kräusslich HG; Rezácová P; Konvalinka J; Bodem J
Antimicrob Agents Chemother; 2012 Aug; 56(8):4320-30. PubMed ID: 22644035
[TBL] [Abstract][Full Text] [Related]
12. Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters.
Gall A; Kaye S; Hué S; Bonsall D; Rance R; Baillie GJ; Fidler SJ; Weber JN; McClure MO; Kellam P;
Retrovirology; 2013 Jan; 10():8. PubMed ID: 23331949
[TBL] [Abstract][Full Text] [Related]
13. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
Kaufmann GR; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper DA
AIDS Res Hum Retroviruses; 2001 Apr; 17(6):487-97. PubMed ID: 11350662
[TBL] [Abstract][Full Text] [Related]
14. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.
Perrier M; Castain L; Regad L; Todesco E; Landman R; Visseaux B; Yazdanpanah Y; Rodriguez C; Joly V; Calvez V; Marcelin AG; Descamps D; Charpentier C
J Antimicrob Chemother; 2019 Jun; 74(6):1679-1692. PubMed ID: 30768160
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
Zhang YM; Imamichi H; Imamichi T; Lane HC; Falloon J; Vasudevachari MB; Salzman NP
J Virol; 1997 Sep; 71(9):6662-70. PubMed ID: 9261388
[TBL] [Abstract][Full Text] [Related]
17. Evolution and biological characterization of human immunodeficiency virus type 1 subtype E gp120 V3 sequences following horizontal and vertical virus transmission in a single family.
Sato H; Shiino T; Kodaka N; Taniguchi K; Tomita Y; Kato K; Miyakuni T; Takebe Y
J Virol; 1999 May; 73(5):3551-9. PubMed ID: 10196244
[TBL] [Abstract][Full Text] [Related]
18. Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaoundé, Cameroon.
Teto G; Tagny CT; Mbanya D; Fonsah JY; Fokam J; Nchindap E; Kenmogne L; Njamnshi AK; Kanmogne GD
Sci Rep; 2017 Oct; 7(1):14136. PubMed ID: 29074854
[TBL] [Abstract][Full Text] [Related]
19. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
[TBL] [Abstract][Full Text] [Related]
20. Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy.
Ghaffari G; Passalacqua DJ; Caicedo JL; Goodenow MM; Sleasman JW
Pediatrics; 2004 Nov; 114(5):e604-11. PubMed ID: 15492356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
